{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T01:24:25Z","timestamp":1760318665799},"reference-count":18,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2000,5,1]],"date-time":"2000-05-01T00:00:00Z","timestamp":957139200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,24]],"date-time":"2019-12-24T00:00:00Z","timestamp":1577145600000},"content-version":"vor","delay-in-days":7176,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2000,5]]},"DOI":"10.1023\/a:1008307528519","type":"journal-article","created":{"date-parts":[[2002,12,22]],"date-time":"2002-12-22T14:41:38Z","timestamp":1040568098000},"page":"595-598","source":"Crossref","is-referenced-by-count":57,"title":["Gemcitabine for relapsed or resistant lymphoma"],"prefix":"10.1016","volume":"11","author":[{"given":"D.G.","family":"Savage","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.A.","family":"I Rule","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Tighe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.J.","family":"Garrett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.M.","family":"Oster","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.T.","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Ruiz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Heitjan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.L.","family":"Keohan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Flamm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.A.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1023\/A:1008307528519_bb0005","first-page":"3","article-title":"Gemcitabine: Pre-clinical pharmacology and mechanisms of action","volume":"23","author":"Plunkett","year":"1996","journal-title":"Semin Oncol"},{"issue":"4","key":"10.1023\/A:1008307528519_bb0010","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1093\/annonc\/10.suppl_4.S234","article-title":"Experimental drugs and drug combinations in pancreatic cancer","volume":"10","author":"Kroep","year":"1999","journal-title":"Ann Oncol"},{"key":"10.1023\/A:1008307528519_bb0015","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1097\/00001813-199908000-00001","article-title":"Phase II trial of gemcitabine as prolonged infusion in metastatic breast cancer","volume":"10","author":"Schmid","year":"1999","journal-title":"Anticancer Drugs"},{"key":"10.1023\/A:1008307528519_bb0020","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1200\/JCO.1997.15.1.310","article-title":"Maximum-tolerated dose defined for single-agent gemcitabine: A phase I dose-escalation study in chemotherapy-naive patients with advanced non-small-cell lung cancer","volume":"15","author":"Fossella","year":"1997","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1023\/A:1008307528519_bb0025","doi-asserted-by":"crossref","first-page":"S53","DOI":"10.1093\/annonc\/10.suppl_5.S53","article-title":"The role of single-agent gemcitabine in the treatment of non-small-cell lung cancer","volume":"10","author":"Kelly","year":"1999","journal-title":"Ann Oncol"},{"key":"10.1023\/A:1008307528519_bb0030","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1097\/00001813-199102000-00007","article-title":"Comparison of antineoplastic activity of 2\u2019,2\u2019-difluorodeoxycytidine and cytosine arabinoside against human myeloid and lymphoid leukemic cells","volume":"2","author":"Bouffard","year":"1991","journal-title":"Anticancer Drugs"},{"key":"10.1023\/A:1008307528519_bb0035","first-page":"47","article-title":"Evaluation of the cytotoxic activity of gemcitabine in primary cultures of tumor cells from patients with hematologic or solid tumors","volume":"22","author":"Csoka","year":"1995","journal-title":"Semin Oncol"},{"key":"10.1023\/A:1008307528519_bb0040","first-page":"203","article-title":"Ohm L","volume":"101","author":"Bernell","year":"1998","journal-title":"Promising activity of gemcitabine in refractory high-grade non-Hodgkin\u2019s lymphoma. Br J Haematol"},{"key":"10.1023\/A:1008307528519_bb0045","first-page":"3786","article-title":"Santoro A, Hiddeman W et al","volume":"17","author":"Fassa","year":"1999","journal-title":"Gemcitabine as a single agent in the treatment of relapsed or refractory aggressive non-Hodgkin\u2019s lymphoma. J Clin Oncol"},{"key":"10.1023\/A:1008307528519_bb0050","doi-asserted-by":"crossref","first-page":"2627","DOI":"10.1200\/JCO.1999.17.8.2625","article-title":"Gemcitabine is active in relapsed Hodgkin\u2019s disease","volume":"17","author":"Lucas","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1023\/A:1008307528519_bb0055","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1023\/A:1008409601731","article-title":"Therapy with gemcitabine in pretreated peripheral T-cell lymphoma patients","volume":"9","author":"Zinzani","year":"1998","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1023\/A:1008307528519_bb0060","first-page":"659a","article-title":"Therapy with gemcitabine in 44 pretreated peripheral T-cell lymphoma patients","volume":"94","author":"Zinzani","year":"1999","journal-title":"Blood"},{"issue":"1","key":"10.1023\/A:1008307528519_bb0065","first-page":"95a","article-title":"Phase II study of gemcitabine in patients with refractory or relapsing low-grade lymphoprohferative malignancies","volume":"94","author":"Dumontet","year":"1999","journal-title":"Blood"},{"key":"10.1023\/A:1008307528519_bb0070","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1023\/A:1008487932384","article-title":"Clinical results of a pharmacodynamically-based strategy for higher dosing of gemcitabine in patients with solid tumors","volume":"9","author":"Touroutoglou","year":"1998","journal-title":"Ann Oncol"},{"key":"10.1023\/A:1008307528519_bb0075","first-page":"42","article-title":"Schedule-dependent antitumor effect of gemcitabine in in vivo model system","volume":"22","author":"Braakhuis","year":"1995","journal-title":"Semin Oncol"},{"key":"10.1023\/A:1008307528519_bb0080","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1038\/bjc.1996.382","article-title":"A phase I study of a 24-hour infusion of gemcitabine in previously untreated patients with inoperable non-small-cell lung cancer","volume":"74","author":"Anderson","year":"1996","journal-title":"Br J Cancer"},{"key":"10.1023\/A:1008307528519_bb0085","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1023\/A:1005817024382","article-title":"Prolonged infusion gemcitabine: a clinical phase I study at low- (300 mg\/m2) and high-dose (875 mg\/m2) levels","volume":"15","author":"Pollera","year":"1997","journal-title":"Invest New Drugs"},{"issue":"1","key":"10.1023\/A:1008307528519_bb0090","first-page":"261b","article-title":"A gemcitabine, cisplatin, and dex-amethazone combination in patients with multiply relapsed Hodgkin\u2019s and non-Hodgkin\u2019s lymphoma","volume":"94","author":"Emmanouilides","year":"1999","journal-title":"Blood"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419550657?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753419550657?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/academic.oup.com\/annonc\/article-pdf\/11\/5\/595\/19478254\/11-5-595.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,2,20]],"date-time":"2020-02-20T07:15:58Z","timestamp":1582182958000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753419550657"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2000,5]]},"references-count":18,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2000,5]]}},"alternative-id":["S0923753419550657"],"URL":"https:\/\/doi.org\/10.1023\/a:1008307528519","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2000,5]]}}}